EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Relief

Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. 

Researchers on the randomized, placebo-controlled EFFISAYIL 2 trial evaluated the efficacy of spesolimab in controlling symptoms and improving outcomes in patients with clear or nearly clear skin. Patients had a history of ≥2 GPP flares in the prior year and received either a loading dose of spesolimab 600 mg subcutaneously plus 300 mg SC every 4 weeks, or placebo. Almost 90% of patients had a GPP Physician Global Assessment (GPPGA) score of 1 at baseline.

According to the results, 63.3% of patients on spesolimab saw sustained improvement in skin symptoms vs. 29.0% in the placebo group. The data showed improvements in pustulation, scaling, and erythema as early as 4 weeks into treatment. Almost a quarter (24.1%) of patients on spesolimab experienced sustained QoL improvements vs. 3.2% on placebo.

“These findings demonstrate that spesolimab (600 mg SC LD; 300 mg SC q4w) provides sustained control of chronic GPP symptoms and leads to meaningful, long-term QoL benefits,” the authors wrote in the study. “Combined evaluation of GPPGA and DLQI provides a more holistic understanding of treatment efficacy in GPP.”

Source: Gordon K, et al. JAAD. 2025. doi:10.1016/j.jaad.2025.01.089